|
Malignant neoplasm of breast
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
Subsequent studies showed that BME treatment of breast cancer cells inhibited survivin and claspin expression.
|
20179194 |
2010 |
|
Malignant neoplasm of breast
|
0.340 |
Biomarker
|
disease |
BEFREE |
We resequenced CLSPN from the germline of selected cancer families with a history of breast cancer (n = 25) or a multicancer phenotype (n = 46) as well as from a panel of sporadic cancer cell lines (n = 52) derived from a variety of tumor types.
|
19737971 |
2009 |
|
Malignant neoplasm of breast
|
0.340 |
Biomarker
|
disease |
BEFREE |
Many previously identified susceptibility factors act in similar functional pathways as claspin, suggesting possible involvement of CLSPN in heritable breast cancer susceptibility.
|
18077083 |
2008 |
|
Malignant neoplasm of breast
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
A separate analysis of the CLSPN c.3839C>T (rs35490896) variant that was observed more frequently in breast tumors than in pancreatic tumors or normal controls failed to detect a significant association with breast cancer risk in a Mayo Clinic breast cancer case-control study.
|
18281469 |
2008 |
|
Malignant neoplasm of breast
|
0.340 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Malignant Neoplasms
|
0.060 |
GeneticVariation
|
group |
BEFREE |
In addition, we identified three heterozygous candidate missense variants in known cancer susceptibility genes (BMPR1A, BRIP1, and SRC), three truncating variants in possibly novel cancer genes (CLSPN, SEC24B, SSH2) and four candidate missense variants in ACACA, NR2C2, INPP4A, and DIDO1.
|
30809968 |
2019 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
As expected for a protein with key roles in checkpoint signalling and genome duplication, aberrations of Claspin expression and structure have been observed in cancer.
|
29931808 |
2019 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Being a key player in the replication stress response, checkpoint activation, and the DNA damage response, Claspin constitutes an attractive therapeutic target in cancer, namely for radio- and chemo-sensitization.
|
30798932 |
2019 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
Being a key player in the replication stress response, checkpoint activation, and the DNA damage response, Claspin constitutes an attractive therapeutic target in cancer, namely for radio- and chemo-sensitization.
|
30798932 |
2019 |
|
Primary malignant neoplasm
|
0.060 |
AlteredExpression
|
group |
BEFREE |
As expected for a protein with key roles in checkpoint signalling and genome duplication, aberrations of Claspin expression and structure have been observed in cancer.
|
29931808 |
2019 |
|
Primary malignant neoplasm
|
0.060 |
GeneticVariation
|
group |
BEFREE |
In addition, we identified three heterozygous candidate missense variants in known cancer susceptibility genes (BMPR1A, BRIP1, and SRC), three truncating variants in possibly novel cancer genes (CLSPN, SEC24B, SSH2) and four candidate missense variants in ACACA, NR2C2, INPP4A, and DIDO1.
|
30809968 |
2019 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
To conclude, we will discuss means by which Claspin can be targeted for cancer therapy.
|
28942358 |
2017 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
To conclude, we will discuss means by which Claspin can be targeted for cancer therapy.
|
28942358 |
2017 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
The expression levels of TopBP1 and Claspin were increased in the cancer cells that survived radiation therapy.
|
25216549 |
2014 |
|
Primary malignant neoplasm
|
0.060 |
AlteredExpression
|
group |
BEFREE |
The expression levels of TopBP1 and Claspin were increased in the cancer cells that survived radiation therapy.
|
25216549 |
2014 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Taken together, these observations raise the possibility that CLSPN may encode a component of the DNA-damage response pathway that is targeted by mutations in human cancers, suggesting the need for larger population-based studies to investigate whether CLSPN variants contribute to cancer susceptibility.
|
19737971 |
2009 |
|
Primary malignant neoplasm
|
0.060 |
GeneticVariation
|
group |
BEFREE |
Taken together, these observations raise the possibility that CLSPN may encode a component of the DNA-damage response pathway that is targeted by mutations in human cancers, suggesting the need for larger population-based studies to investigate whether CLSPN variants contribute to cancer susceptibility.
|
19737971 |
2009 |
|
Breast Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Subsequent studies showed that BME treatment of breast cancer cells inhibited survivin and claspin expression.
|
20179194 |
2010 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
We resequenced CLSPN from the germline of selected cancer families with a history of breast cancer (n = 25) or a multicancer phenotype (n = 46) as well as from a panel of sporadic cancer cell lines (n = 52) derived from a variety of tumor types.
|
19737971 |
2009 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Many previously identified susceptibility factors act in similar functional pathways as claspin, suggesting possible involvement of CLSPN in heritable breast cancer susceptibility.
|
18077083 |
2008 |
|
Breast Carcinoma
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
A separate analysis of the CLSPN c.3839C>T (rs35490896) variant that was observed more frequently in breast tumors than in pancreatic tumors or normal controls failed to detect a significant association with breast cancer risk in a Mayo Clinic breast cancer case-control study.
|
18281469 |
2008 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Accumulating evidence suggests that Claspin inactivation could be an essential event during carcinogenesis, indicating that Claspin may function as a tumour suppressor.
|
28942358 |
2017 |
|
Carcinogenesis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Accumulating evidence suggests that Claspin inactivation could be an essential event during carcinogenesis, indicating that Claspin may function as a tumour suppressor.
|
28942358 |
2017 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
In order to investigate whether claspin immunoreactivity is related to the lesion severity and High-Risk (HR) HPV infection, we analyzed claspin expression by immunohistochemistry in a series of cervical biopsies which represent the steps occurring during cervical carcinogenesis (normal tissues, Cervical Intraepithelial Neoplasias 1, 2 and 3, Squamous Cell Carcinomas).
|
22731782 |
2012 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
In order to investigate whether claspin immunoreactivity is related to the lesion severity and High-Risk (HR) HPV infection, we analyzed claspin expression by immunohistochemistry in a series of cervical biopsies which represent the steps occurring during cervical carcinogenesis (normal tissues, Cervical Intraepithelial Neoplasias 1, 2 and 3, Squamous Cell Carcinomas).
|
22731782 |
2012 |